Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer

Mary Cianfrocca, Antonio C. Wolff

Research output: Contribution to journalReview articlepeer-review

Abstract

The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have challenged this standard in postmenopausal women, and ongoing trials are examining the optimal use of endocrine therapy in younger women. Issues regarding the optimal approach to endocrine therapy in both pre- and postmenopausal women are examined in this review.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalONCOLOGY
Volume21
Issue number1
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer'. Together they form a unique fingerprint.

Cite this